Found: 3
Select item for more details and to access through your institution.
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta‐analysis.
- Published in:
- Pigment Cell & Melanoma Research, 2024, v. 37, n. 3, p. 352, doi. 10.1111/pcmr.13156
- By:
- Publication type:
- Article
Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1399171
- By:
- Publication type:
- Article
Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 12, p. 13217, doi. 10.1002/cam4.6013
- By:
- Publication type:
- Article